TRCT
TNGX icon

Tower Research Capital (TRC)’s Tango Therapeutics TNGX Stock Holding History

Tower Research Capital (TRC)’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$352K Sell
11,260
-1,277
-10% -$31.6K 0.01% 1269
2026
Q1 		$262K Sell
12,537
-7,204
-36% -$100K 0.01% 1410
2025
Q4 		$175K Buy
19,741
+13,297
+206% +$115K ﹤0.01% 1544
2025
Q3 		$54.1K Sell
6,444
-3,029
-32% -$20.5K ﹤0.01% 2468
2025
Q2 		$48.5K Buy
9,473
+2,907
+44% +$7.19K ﹤0.01% 2999
2025
Q1 		$8.99K Buy
6,566
+757
+13% +$1.86K ﹤0.01% 3836
2024
Q4 		$17.9K Sell
5,809
-8,956
-61% -$41.6K ﹤0.01% 3278
2024
Q3 		$114K Sell
14,765
-917
-6% -$8.75K ﹤0.01% 2131
2024
Q2 		$135K Buy
15,682
+14,243
+990% +$110K ﹤0.01% 2369
2024
Q1 		$11.4K Sell
1,439
-11,770
-89% -$126K ﹤0.01% 3567
2023
Q4 		$131K Buy
13,209
+11,761
+812% +$102K ﹤0.01% 2430
2023
Q3 		$16.3K Sell
1,448
-1,421
-50% -$8.66K ﹤0.01% 3566
2023
Q2 		$9.53K Sell
2,869
-10,454
-78% -$37.6K ﹤0.01% 4265
2023
Q1 		$52K Buy
13,323
+10,101
+314% +$58.6K ﹤0.01% 2462
2022
Q4 		$23K Sell
3,222
-18
-0.6% -$127 ﹤0.01% 3008
2022
Q3 		$12K Buy
3,240
+1,028
+46% +$4.39K ﹤0.01% 4376
2022
Q2 		$10K Buy
2,212
+2,112
+2,112% +$12.8K ﹤0.01% 4487
2022
Q1 		$1K Buy
+100
New +$867 ﹤0.01% 5861
2021
Q4 		– Sell
-828
Closed -$11K – 6566
2021
Q3 		$11K Buy
+828
New +$9.93K ﹤0.01% 4258
2021
Q2 		– Sell
-17
Closed – – 5844
2021
Q1 		$0 Buy
+17
New +$196 ﹤0.01% 5727

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Tower Research Capital (TRC)'s TNGX Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Tango Therapeutics (TNGX) stake by 10% in Q2 2026, selling an estimated $31.6K and leaving 11,260 shares worth $352K. The position accounts for 0.01% of the portfolio, ranked #1269.

Tower Research Capital (TRC) first reported a position in TNGX in Q1 2021 and has held it in 20 quarters since. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Tower Research Capital (TRC) held 11,260 shares of Tango Therapeutics worth $352K as of Q2 2026.
  • Tower Research Capital (TRC) sold 1,277 Tango Therapeutics shares in Q2 2026, an estimated $31.6K.
  • Tango Therapeutics made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1269 holding.
  • Tower Research Capital (TRC) first reported a position in Tango Therapeutics in Q1 2021 and has held it in 20 quarters since.
  • 248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.